Aclaris Therapeutics announced positive Phase 1b proof-of-concept results for its bispecific antibody ATI-052 targeting TSLP and IL-4Rα in atopic dermatitis (AD) and asthma. The trials showed rapid, broad, and durable improvements in skin symptoms and lung function with a favorable safety profile, including no conjunctivitis. ATI-052 demonstrated potential best-in-class activity by modulating multiple inflammatory pathways and showed promise for further development, especially in eosinophilic esophagitis (EoE), where Phase 2b trials are planned. These results highlight ATI-052’s potential as a potent treatment for diverse immuno-inflammatory diseases.
Aclaris Therapeutics' positive Phase 1b results for ATI-052 provide context alongside Pluang's Health-sector market snapshot as of Oct 27, 2026 16:11 WIB. Of 150 priced Health-sector US stocks tradable on Pluang, 61 rose and 75 fell today. Notable movers include CRON at USD 3.41 (+3.02%), ALMS at USD 6.70 (+2.92%), and ACAD at USD 20.28 with 100% buy order activity and a typical hold time of 77 days.
Nautilus Biotechnology announced its Q3 2026 financial results, reporting $0.2 million in revenue mainly from grants and early access services, and a net loss of $15.6 million. The company highlighted progress in its proteome analysis platform, inclu...
Eviden, part of Atos Group, has introduced ASTRA-LAS, a tactical decision-support solution designed to aid naval officers in complex maritime environments. The system uses operational data and AI to enhance situational awareness, reduce cognitive loa...
Eviden, part of Atos Group, has introduced ASTRA-LAS, a new AI-powered tactical assistant designed to support naval operations by providing enhanced visualizations, automated analyses, and mission-specific recommendations. This system helps naval off...
Investec Bank plc, acting as joint broker for Pollen Street Group Limited, disclosed share transactions on October 26, 2026. The bank purchased and sold 20,765 ordinary shares at prices ranging from 929 to 935 per share. There were no derivative tran...
Investec Bank Plc, acting as financial adviser to DBAY Advisors Limited, purchased 50,000 ordinary shares of Logistics Development Group plc on October 26, 2026, at a price of 21.5 per share. This transaction was disclosed under Rule 8.5 of the Takeo...
